MediWorkAI
Category: AI in Healthcare
Medical AI data annotation and clinical validation platform powered by a network of 1,200+ specialist physicians MediWorkAI was founded in 2025. The company is led by Yoon Seungkyu (윤승규). Based in Seoul, South Korea. Team size: 1-10. Latest round: Seed. Key investors include Korea Investment Accelerator (한국투자액셀러레이터), Aseptic Asia (아셉틱아시아), CrowdWorks (크라우드웍스).
- Founded
- 2025
- Headquarters
- Seoul, South Korea
- Team size
- 1-10
Value proposition
MediWorkAI is a medical AI MLOps company that bridges the gap between AI development and clinical practice by providing high-quality physician-generated data annotation (T1), AI model evaluation and improvement (T2), and independent blinded clinical validation (T3) — the latter being a critical requirement for MFDS and FDA regulatory approvals.
Products and solutions
DoctorWorks platform: T1 (Medical data annotation by specialists), T2 (AI model evaluation/comparison/improvement by physicians), T3 (Independent blinded clinical validation panel with named reports for regulatory submission)
Unique value
Only company in Korea offering external independent clinical validation (T3) for medical AI that can be used as evidence for MFDS and FDA regulatory submissions; 1,200+ specialists across all 25 medical departments; end-to-end MLOps from data annotation to regulatory-grade validation
Target customer
Medical AI developers, healthcare institutions, pharmaceutical companies, and medical device companies needing regulatory-grade clinical validation and high-quality medical data annotation
Industries served
Healthcare AI, Medical Device, Digital Therapeutics, Clinical Research
Technology advantage
25-department, 1,200+ specialist physician network; proprietary blind clinical validation panel methodology; first-mover advantage in Korea's regulatory-driven recurring validation market (Digital Medical Device Law & Korean PCCP mandates re-validation on every AI model update)
How they differentiate
Unlike medical AI companies focused on developing their own AI diagnostic algorithms, MediWorkAI is a pure-play medical AI infrastructure/MLOps company that provides the data annotation and clinical validation services that other AI developers need. Its T3 blinded clinical validation service is uniquely positioned as the only external provider in Korea for MFDS/FDA regulatory submission evidence.
Main competitors
Lunit, VUNO (뷰노), Deepnoid (딥노이드)
Key partnerships
Aseptic Asia (co-founder, physician-founded investment firm providing medical expertise), CrowdWorks (KOSDAQ-listed AI data company, providing data business know-how and sales network), Korea Investment Accelerator (investor via 'Barun Donghaeng' acceleration program), FastCampus (AI education program development), Seoul St. Mary's Hospital (neuropsychology R&D voucher project), Douzone Bizon (ASMI seminar participation)
Major milestones
2025-10: Company founded, 2025-12: Co-founded by Aseptic Asia, 2026-02: Aseptic Asia's Dr.Alice AI solution strategically supplied to MediWorkAI, 2026-03: Established corporate-affiliated research institute, 2026-03: FastCampus AI education program development, 2026-05: Seoul St. Mary's Hospital neuropsychology R&D voucher project, 2026-06: Selected for Korea Investment Accelerator's 'Barun Donghaeng' program with TIPS Seed investment, 2026-07: Participated in Douzone Bizon ASMI seminar
Market positioning
Early-stage medical AI infrastructure/MLOps company positioned as the essential validation layer for Korea's medical AI ecosystem, benefiting from structural regulatory tailwinds (Digital Medical Device Law mandating re-validation on AI model updates)
Geographic focus
South Korea (primary), with stated plans to expand into Asia and global markets
About Yoon Seungkyu (윤승규)
Ex-CEO of DoctorWorks (닥터웍스), a subsidiary of CrowdWorks (KOSDAQ-listed AI data company); background in healthcare, pharma/biotech, and AI business management
Latest news about MediWorkAI
More AI in Healthcare companies
Official website: https://www.doctorworks.kr/